Pamabrom
[CAS# 606-04-2]

Identification

• Classification: Analytical chemistry >> Analytical reagent >> Ion chromatography reagent
• Name: Pamabrom
• Synonyms: 2-Amino-2-methylpropanol 8-bromotheophyllinate
• Molecular Formula: C₇H₇BrN₄O₂.C₄H₁₁NO;C₁₁H₁₈BrN₅O₃
• Molecular Weight: 348.20
• CAS Registry Number: 606-04-2
• EC Number: 210-103-4
• SMILES: CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br

Properties

• Solubility: 10 mM (DMSO)

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302
• Safety Statements: P264-P270-P301+P317-P330-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute toxicity	Acute Tox.	4	H302

Discovery and Applications

The diuretic pamabrom was discovered in the mid-20th century and has since been widely used in medical treatment. Originally synthesized to treat fluid retention disorders, pamabrom's efficacy lies in its ability to increase urine output without significantly altering electrolyte balance. This property makes it valuable in treating conditions such as menstrual-related edema and some forms of bloating.

Pamabrom's mechanism of action involves stimulation of renal tubular function, thereby promoting the excretion of excess fluid and reducing swelling. Unlike some diuretics that can cause potassium deficiency, pamabrom generally maintains electrolyte levels within the normal range, enhancing its safety for short-term therapeutic use.

In addition to its medical uses, pamabrom is used in pharmaceutical formulations designed to relieve symptoms of premenstrual syndrome (PMS) and associated menstrual discomfort. Its inclusion in over-the-counter medications highlights its accessibility and widespread acceptance among consumers seeking relief from temporary fluid retention.

Research is ongoing to optimize pamabrom's efficacy and explore its potential applications in related therapeutic areas. As the understanding of its pharmacological properties continues to evolve, pamabrom remains a key component in the management of diseases where fluid balance regulation is critical.

References

2024. Patch Testing to the Rescue! Lesional Testing for Diagnosis of Fixed Drug Eruption to Pamabrom. Dermatitis: Contact, Atopic, Occupational, Drug, 35(4).
DOI: 10.1089/derm.2023.0116

2023. Effect of nitric oxide-cyclic GMP-K+ channel pathway blockers, naloxone and metformin, on the antinociception induced by the diuretic pamabrom. Canadian Journal of Physiology and Pharmacology, 101(3).
DOI: 10.1139/cjpp-2022-0277

2016. Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial. Medwave, 16(9).
DOI: 10.5867/medwave.2016.09.6587